NGT: Act Against Pharma Co. For Unsafe Disposal Of Biomed Waste

Chennai : The National Green Tribunal (NGT) has directed Tamil Nadu Pollution Control Board (TNPCB) to act against a Chennai-based pharma company for unsafe disposal of biomedical waste.

Inter Med, which has a tablet manufacturing unit in Porur, had dumped hazardous waste at a private land abutting Alapakkam Main Road. The corporation which spotted this violation collected a fine of ₹5,000 from the firm in August 2021.

But there was no follow-up action by the TNPCB. So, NGT Southern Zone, which was recently hearing a case pertaining to biomedical waste in Chennai, called this ‘unfortunate’ and directed the board to collect compensation from the firm.

During the hearing, GCC claimed that it had installed 50 CCTV cameras at vulnerable locations (of waste dumping) and a team at Ripon Buildings was monitoring the situation round the clock.

The civic body further told the tribunal that violators were booked under various provisions under the Biomedical Waste Management Rules, 2016 and in one such case (reported at Sri Lakshmi Nagar in Valasaravakkam) they had lodged a police complaint.

Besides this, the tribunal has told TNPCB to explore the possibility of tracing the total purchase and disposal of biomedical articles by healthcare units so that there is 100% transparency in the process. The NGT has given four months’ time to the board to submit a report regarding this.

At present, there are 4,240 healthcare facilities within the corporation limit, according to official data. All of them have obtained authorisation from the TNPCB to safely dispose of the biomed waste through agreements executed with two common biomedical waste treatment facilities.

  • Related Posts

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Milan: CPHI Milan 2026, one of the pharmaceutical industry’s largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the…

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Washington: Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. But the buzz surrounding the effectiveness of the compound—commonly known as triple-G—has already triggered a…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch